Bone Biologics Corporation (BBLG) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Les analystes estiment Bénéfice par action (EPS) de $-19.02 et chiffre d'affaires de $0.00B pour le prochain exercice fiscal.
Historique du Bénéfice par action (EPS): 2024: réel $-4.83 vs est $-19.02 (dépassé +74.6%). 2025: réel $-2.65 vs est $-2.36 (manqué -12.3%). Précision des analystes: 0%.
